Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prasugrel Delay Shifts Focus To Possible August Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA extends user fee date for the novel anti-platelet drug to Sept. 26.

You may also be interested in...



Prasugrel Delay Could Extend Well Into 2009; FDA Eyes February Cmte. Review

It looks like FDA's decision on Lilly's anti-clotting drug prasugrel won't come before March 2009 at the earliest

Prasugrel Delay Could Extend Well Into 2009; FDA Eyes February Cmte. Review

It looks like FDA's decision on Lilly's anti-clotting drug prasugrel won't come before March 2009 at the earliest

Prasugrel Round Two: Is FDA Approval In Sight?

FDA action on Eli Lilly/Daiichi Sankyo’s clot buster anticipated Sept. 26.

Related Content

Topics

UsernamePublicRestriction

Register

PS067975

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel